Bindwell is testing a simple idea: use AI to design smarter, more targeted pesticides built for today’s farming challenges.
Updated
November 14, 2025 10:48 PM

Researcher tending seedlings in a laboratory environment. PHOTO: FREEPIK
Bindwell, a San Francisco–based ag-tech startup using AI to design new pesticide molecules, has raised US$6 million in seed funding, co-led by General Catalyst and A Capital, with participation from SV Angel and Y Combinator founder Paul Graham. The round will help the company expand its lab in San Carlos, hire more technical talent and advance its first pesticide candidates toward validation.
Even as pesticide use has doubled over the last 30 years, farmers still lose up to 40% of global crops to pests and disease. The core issue is resistance: pests are adapting faster than the industry can update its tools. As a result, farmers often rely on larger amounts of the same outdated chemicals, even as they deliver diminishing returns.
Meanwhile, innovation in the agrochemical sector has slowed, leaving the industry struggling to keep up with rapidly evolving pests. This is the gap Bindwell is targeting. Instead of updating old chemicals, the company uses AI to find completely new compounds designed for today’s pests and farming conditions.
This vision is made even more striking by the people leading it. Bindwell was founded by 18-year-old Tyler Rose and 19-year-old Navvye Anand, who met at the Wolfram Summer Research Program in 2023. Both had deep ties to agriculture — Rose in China and Anand in India — witnessing up close how pest outbreaks and chemical dependence burdened farmers.
Filling the gap in today’s pesticide pipeline, Bindwell created an AI system that can design and evaluate new molecules long before they hit the lab. It starts with Foldwell, the company’s protein-structure model, which helps map the shapes of pest proteins so scientists know where a molecule should bind. Then comes PLAPT, which can scan through every known synthesized compound in just a few hours to see which ones might actually work. For biopesticides, they use APPT, a model tuned to spot protein-to-protein interactions and shown to outperform existing tools on industry benchmarks.
Bindwell isn’t selling AI tools. Instead, the company develops the molecules itself and licenses them to major agrochemical players. Owning the full discovery process lets the team bake in safety, selectivity and environmental considerations from day one. It also allows Bindwell to plug directly into the pipelines that produce commercial pesticides — just with a fundamentally different engine powering the science.
At present, the team is now testing its first AI-generated candidates in its San Carlos lab and is in early talks with established pesticide manufacturers about potential licensing deals. For Rose and Anand, the long-term vision is simple: create pest control that works without repeating the mistakes of the last half-century. As they put it, the goal is not to escalate chemical use but to design molecules that are more precise, less harmful and resilient against resistance from the start.
Keep Reading
Reimagining biodefense at the intersection of AI, biology and urgency.
Updated
November 5, 2025 3:05 PM

Through computational tools, Valthos analyzes biological data to design adaptive solutions against emerging threats. PHOTO: VALTHOS
Valthos has raised US$30 million in seed funding, led by the OpenAI Startup Fund, Lux Capital and Founders Fund, to advance its mission of building next-generation biodefense systems.
The company’s work comes at a time when biotechnology is evolving at an unprecedented pace. Biotechnology is moving at record speed. These new tools can lead to life-changing medical discoveries, but they also bring the risk of dangerous biological agents being developed faster than ever.
“The issue at the core of biodefense is asymmetry”, said Kathleen McMahon, co-founder of Valthos. “It’s easier to make a pathogen than a cure. We’re building tools to help experts at the frontlines of biodefense move as fast as the threats they face”. The gap Valthos aims to close is between the rapid rise of biological threats and the slower pace of developing cures. Therefore, the company is developing AI systems that can rapidly analyze biological sequences and significantly shorten the time needed to design medical countermeasures.
“In this new world, the only way forward is to be faster. So we set out to build a new tech stack for biodefense”, said Tess van Stekelenburg, co-founder of Valthos. “This software infrastructure strengthens biodefense today and lays the groundwork for the adaptive, precision therapeutics of tomorrow”.
The company was founded by van Stekelenburg, a partner at Lux Capital and McMahon, the former head of Palantir’s Life Sciences division. Together, they’ve built a multidisciplinary team of experts from Palantir, DeepMind, Stanford’s Arc Institute and MIT’s Broad Institute, bringing together deep experience in software engineering, machine learning and biotechnology.
“Technology is moving fast. An industrial ecosystem of builders, companies and solutions further democratizes AI to provide broad resilience, and ensures the U.S. continues to lead as AI increasingly powers everything around us. As AI and biotech rapidly advance, biodefense is one of the new industry verticals that helps maximize the benefits and minimize the risks”, said Jason Kwon, OpenAI’s Chief Strategy Officer. “Valthos is pushing the frontier of protection and defense in one of the most strategic intersections of multiple world-changing technologies, and with the team to do it”.
Looking ahead, Valthos plans to expand its engineering team and scale its software infrastructure for both government and commercial partners — moving closer to its goal of enabling faster, smarter and more adaptive biodefense capabilities.